Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

摘要: The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, progressive NSCLC, previously treated chemotherapy, received oral 250 mg daily. first 39 alone (G group). other 31 also subcutaneous (GIL-2 group): 1 MIU/m2 (Million International Unit/m2)twice a day on Days 2, once 3, 4, 5 every week four weeks four-week rest period. Median follow-up was 25.2 months. Grade 3-4 toxicity represented skin rash (7%), asthenia/anorexia (6%) diarrhea (7%); showed grade 2-3 fever (46%), fatigue (21%) arthralgia (13%). GIL-2 group G-group, respectively observed: an overall response rate 16.1% (6.4% complete response) 5.1% (only partial response); disease control 41.9% 41%; median time progression 3.5 (CI 95% = 3.2-3.8) 4.1 2.6-5.7) months; survival 20.1 5.1-35.1) 6.9 4.9-8.9) months (p 0.002); actuarial one-year 54% 30%. Skin < 0.001; HR 0.29; CI 0.16-0.54) use 0.33; 0.18-0.60) were independently associated improvement survival. consecutive, non-randomized, series advanced NSCLC patients, increased efficacy gefitinib.